Haloperidol drug

3 to 12 years and 15 to 40 kg:
-Initial dose: mg/day orally in 2 to 3 divided doses
-Maintenance dose: to mg/kg/day

-The daily dose may be increased every 5 to 7 days in mg increments.
-There is little evidence that behavior improvement is further enhanced by doses greater than 6 mg/day.
-Limitation of use: Treatment should be reserved for patients with severe behavior problems and/or hyperactive children only after failure to respond to psychotherapy or medications (other than antipsychotics).

-Treatment of severe behavior problems in children, including combative, explosive hyperexcitability not accounted for by immediate provocation
-Short-term treatment of hyperactive children with excessive motor activity and accompanying conduct disorder with impulsivity, difficulty sustaining attention, aggressiveness, mood lability, and/or poor frustration tolerance.

MMDA was described by Alexander Shulgin in his book PiHKAL . Shulgin lists the dosage range of MMDA as 100–250 mg. The first symptoms appear within 30–60 minutes following oral administration . MMDA produces euphoria and loving warmth, and attenuates feelings such as anxiety and loneliness . MMDA also produces eyes-closed visuals , a state of drowsiness , muscle relaxation , and time dilation . Side effects include moderate mydriasis , dizziness , sensations of heat or cold , and trembling . The imagery is generally realistic, and often related to everyday perception of people, landscapes, or objects. The effects of MMDA usually reach a peak during the first hour following the initial symptoms, and begin to wane during the second hour, and usually completely disappear by the end of the fifth hour.


Haloperidol drug

haloperidol drug


haloperidol drughaloperidol drughaloperidol drughaloperidol drughaloperidol drug